Joop C. van Oene

809 total citations
24 papers, 652 citations indexed

About

Joop C. van Oene is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Joop C. van Oene has authored 24 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Cellular and Molecular Neuroscience and 6 papers in Psychiatry and Mental health. Recurrent topics in Joop C. van Oene's work include Receptor Mechanisms and Signaling (9 papers), Neurotransmitter Receptor Influence on Behavior (9 papers) and Neuroscience and Neuropharmacology Research (6 papers). Joop C. van Oene is often cited by papers focused on Receptor Mechanisms and Signaling (9 papers), Neurotransmitter Receptor Influence on Behavior (9 papers) and Neuroscience and Neuropharmacology Research (6 papers). Joop C. van Oene collaborates with scholars based in Netherlands, Belgium and Spain. Joop C. van Oene's co-authors include Alan S. Horn, John W. Kebabian, Jan B. De Vries, M C Coene, Adam F. Cohen, Aernout D. van Haarst, Rik C. Schoemaker, Joop van Gerven, Takashi Agui and Kazuto Shigematsu and has published in prestigious journals such as Gastroenterology, The Lancet Neurology and Trends in Pharmacological Sciences.

In The Last Decade

Joop C. van Oene

21 papers receiving 618 citations

Peers

Countries citing papers authored by Joop C. van Oene

Since Specialization

Citations

This map shows the geographic impact of Joop C. van Oene's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joop C. van Oene with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joop C. van Oene more than expected).

Fields of papers citing papers by Joop C. van Oene

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joop C. van Oene. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joop C. van Oene. The network helps show where Joop C. van Oene may publish in the future.

Co-authorship network of co-authors of Joop C. van Oene

This figure shows the co-authorship network connecting the top 25 collaborators of Joop C. van Oene. A scholar is included among the top collaborators of Joop C. van Oene based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joop C. van Oene. Joop C. van Oene is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate 2011 ·Psychological Medicine ·Jan K. Buitelaar, Miguel Casas, Alexandra Philipsen, J. J. Sandra Kooij, Josep Antoni Ramos‐Quiroga, (unknown), Joop C. van Oene, Barbara Schäuble	22
2	Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate 2010 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Jan K. Buitelaar, J. J. Sandra Kooij, Josep Antoni Ramos‐Quiroga, Joachim Dejonckheere, Miguel Casas, Joop C. van Oene, Barbara Schäuble, (unknown)	30
3	P.1.i.0311 Predictors of treatment outcome with long-acting methylphenidate in attention deficit hyperactivity disorder in adults 2009 ·European Neuropsychopharmacology ·Josep Antoni Ramos‐Quiroga, J. J. Sandra Kooij, G.-E. Trott, (unknown), (unknown), Joop C. van Oene, Barbara Schäuble, (unknown), Jan K. Buitelaar	0
4	Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial 2008 ·The Lancet Neurology ·Alistair Burns, Roberto Bernabei, Roger Bullock, Alfonso J. Cruz‐Jentoft, Lutz Frölich, Christoph Höck, Minna Raivio, Eric Triau, M. Vandewoude, Anders Wimo, (unknown), B. Van Baelen, (unknown), Joop C. van Oene, S. Schwalen	107
5	Add-on topiramate in the treatment of refractory partial-onset epilepsy: Clinical experience of outpatient epilepsy clinics from 11 general hospitals 2005 ·Seizure ·(unknown), Georgios Georgiadis, (unknown), (unknown), Vasilios Κ. Kimiskidis, (unknown), Anna Karlovasitou, Dimos D. Mitsikostas, (unknown), Panagiotis Polychronopoulos, (unknown), Kleopas Michailidis, (unknown), Kyriakos Garganis, (unknown), (unknown), (unknown), (unknown), Joop C. van Oene	5
6	Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation 2002 ·Alimentary Pharmacology & Therapeutics ·Cornelius E. J. Sloots, Alexander C. Poen, René Kerstens, Marita Stevens, (unknown), Joop C. van Oene, S. G. M. Meuwissen, R. J. F. Felt‐Bersma	73
7	The influence of cisapride and clarithromycin on QT intervals in healthy volunteers 1998 ·Clinical Pharmacology & Therapeutics ·Aernout D. van Haarst, (unknown), Joop van Gerven, Rik C. Schoemaker, Joop C. van Oene, (unknown), M C Coene, Adam F. Cohen	125
8	Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty 1993 ·RePub (Erasmus University, Rotterdam) ·Patrick W. Serruys, Werner Klein, Jan G.P. Tijssen, Wolfgang Rutsch, Guy R. Heyndrickx, Håkan Emanuelsson, Sarah W. Ball, (unknown), (unknown), Henry Liberman, (unknown), James T. Willerson, (unknown), Fareed Khaja, R. Wayne Alexander, Donald S. Baim, Rein Melkert, Joop C. van Oene, (unknown)	23
9	EFFECT OF KETANSERIN ON INTRAOPERATIVE BLOOD LOSS DURING TOTAL HIP ARTHROPLASTY IN ELDERLY PATIENTS UNDER GENERAL ANAESTHESIA 1991 ·British Journal of Anaesthesia ·(unknown), Joop C. van Oene	1
10	Oral dosing with ketanserin to control high blood pressure in the elderly 1990 ·Cardiovascular Drugs and Therapy ·Joop C. van Oene	2
11	Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy 1988 ·European Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), Joop C. van Oene	12
12	Hypertensive Patients with Raynaudʼs Phenomenon or Intermittent Claudication and Their Treatment with Ketanserin 1988 ·Drugs ·Joop C. van Oene	3
13	The D1 dopamine receptor: new perspectives 1986 ·Trends in Pharmacological Sciences ·John W. Kebabian, Takashi Agui, Joop C. van Oene, Kazuto Shigematsu, Juan M. Saavedra	62
14	[125I]SCH 23982: the ligand of choice for identifying the D-1 dopamine receptor 1986 ·European Journal of Pharmacology ·A Sidhu, Joop C. van Oene, (unknown), (unknown), John W. Kebabian	62
15	The effectiveness of yohimbine in blocking rat central dopamine autoreceptors in vivo 1984 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Joop C. van Oene, Jan B. De Vries, Alan S. Horn	42
16	In vivo dopamine autoreceptor selectivity appears to be critically dependent upon the aromatic hydroxyl position in a series of N,N-disubstituted 2-aminotetralins 1984 ·European Journal of Pharmacology ·Joop C. van Oene, Jan B. De Vries, Durk Dijkstra, (unknown), Pieter G. Tepper, Alan S. Horn	32
17	trans-N-n-propyl-7-hydroxy-octahydrobenzo(f)quinoline, a rigid 3-PPP analogue with greater potency but lack of selectivity for dopamine autoreceptors 1983 ·European Journal of Pharmacology ·Joop C. van Oene, (unknown), Durk Dijkstra, Alan S. Horn	2
18	The purported dopamine agonist DPI inhibits [3H]noradrenaline release from rat cortical slices but not [3H]dopamine and [14C]acetylcholine release from rat striatal slices in-vitro 1983 ·Journal of Pharmacy and Pharmacology ·Joop C. van Oene, Peter Sminia, A.H. Mulder, A. S. Horn	10
19	3,4-Disubstituted phenyliminoimidazolidines as potential prodrugs of the purported dopamine agonist 3,4-dihydroxyphenylimino-2-imidazolidine (DPI) 1983 ·Pharmacy World & Science ·(unknown), Joop C. van Oene, A. S. Horn	3
20	Evidence that the purported dopaminergic agonist (3,4-dihydroxyphenylimino)-2-imidazolidine (DPI) may reduce rat striatal dopamine turnover by an α2-adrenergic mechanism 1982 ·European Journal of Pharmacology ·Joop C. van Oene, (unknown), Alan S. Horn	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact